We evaluated the therapeutic effect of erythropoietin (EPO) delivered by direct injection of a nonreplicating herpes simplex virus (HSV)-based vector coding for EPO (vEPO) in a model of cervical hemicord contusion at C7. At 1 h after spinal cord injury (SCI), either vEPO or control vector carrying a reporter gene (vC) was injected into the cord above and below the lesion. Animals injected with vEPO showed a statistically significant improvement in the ipsilateral forelimb function, as measured by open-field evaluation of motor performance, forelimb reaching in the cylinder test and misplacement in grid walk. This correlated with preservation of gray matter in the area of the lesion. There was also mild but significant improvement of hindlimb motor function measured by Basso --Beattie --Bresnahan score and computerized gait analysis in vEPO compared with control vector-injected animals. Microtubule-associated protein tau, phosphorylated and nonphosphorylated neurofilament protein and the synaptic proteins synaptophysin and PSD-95 were all significantly increased in the spinal cord of vEPO-treated animals compared with control vector-injected animals. These data suggest that gene transfer of EPO after cervical SCI by minimizing the injury size and enhancing tissue sparing preserves large-caliber axons and promotes synaptogenesis.
INTRODUCTION
Acute traumatic spinal cord injury (SCI) results in devastating loss of neurological function below the level of injury, and although animal studies have frequently examined thoracic or lumbar models, almost 50% of human SCI occurs at the cervical level. 1 For these patients, even modest recovery of upper extremity function would have a major impact on the quality of life. 2 However, effective pharmacologic treatment is not available.
Erythropoietin (EPO), a cytokine initially characterized for its effects on erythropoiesis, has been demonstrated to have remarkable tissue-protective activity in preclinical models of neuronal, retinal, cardiac and renal ischemic injury. 3 --5 We have previously demonstrated that sustained expression of human EPO achieved by gene transfer using a nonreplicating herpes simplex virus (HSV)-based vector has protective effects on rodent models of Parkinson's disease 6 in the central nervous system, and can protect against the progression of neuropathy in mice with diabetes. 7 Injury to the spinal cord after contusion occurs in two phases: an acute phase reflects acute mechanical damage, and a later secondary phase 8 that involves a complex cascade of molecular events including disturbances of ionic homeostasis, local edema, focal hemorrhage, excitotoxicity, effects of the presence of free radicals and free fatty acids and activation of an inflammatory response. Systemic delivery of EPO has been used in the acute phase of thoracic SCI models with improvement in some but not all of the reported studies. 9 In the current study we investigated the effects of EPO delivered locally to the injured spinal cord by a nonreplicating HSV-based vector expressing rat EPO (vEPO) following acute asymmetric contusion of the cervical spinal cord. We found that vector-mediated expression of EPO reduced tissue damage and improved forelimb and hindlimb motor function, and that the improvement in behavioral measures correlated with increased levels of axonal cytoskeletal proteins and synaptic proteins in the cervical spinal cord as compared with animals treated with control vector.
RESULTS AND DISCUSSION
Characterization of the EPO-expressing HSV vector vEPO in vitro and in vivo Schematic representation of the HSV vector constructs carrying two copies of hemagglutinin (HA)-tagged rat EPO or two copies of green fluorescent protein (vC) are shown in Figure 1a . Characterization of EPO expression following vector transfection was performed in spinal cord neurons in vitro and in cervical spinal cord after injury in vivo. Cultured spinal cord neurons infected with vEPO at a multiplicity of infection of 2 at 14 days after seeding showed synthesis and release of EPO into the culture medium that was quantified by enzyme-linked immunosorbent assay (ELISA) at 2 and 3 days post infection (Figure 1b) . The released EPO detected by ELISA was confirmed by western blot analysis of the cultured medium at 48 h post infection using an anti-HA antibody to detect the rat EPO-HA fusion peptide (Figure 1c) . Similarly, HA-tagged EPO was detected by western blot in cell lysates of spinal cord neurons 72 h after infection with vEPO in vitro (Figure 1d ). No transgene-produced EPO was detected under basal conditions or from cells infected with vC. We had previously determined that HSV vectors injected into the spinal cord remain largely within 1 mm of the injection site (data not shown). Injection of vEPO (4 Â 10 7 PFU per ml) into the cervical spinal cord 1 h after injury (1 ml at two sites just above and below the epicenter of the lesion) resulted in robust EPO mRNA expression that was sustained for more than 14 days (Figure 1e ). For RNA detection, the use of a forward primer with a sequence specific to EPO and a reverse primer with a sequence specific to the HA tag allowed us to detect specifically transgene-produced EPO. Sustained EPO protein expression was measured in lysates by ELISA following vEPO injection into the cervical spinal cord (Figure 1f ). The expression of HA-tagged EPO protein in spinal cord lysates was confirmed by western blot using an anti-HA antibody (Figure 1g ).
Intraspinal injection of vEPO reduces inflammatory response, vascular extravasation and post-traumatic cavity SCI was induced by asymmetric contusion on the right dorsal spinal cord at C7 level. The injuries were identical between the two groups. The mean force at the impact site was 162.57 ± 2.15 Kdyn for the vEPO-treated group and 163.75 ± 3.69 Kdyn for the vC-inoculated group; the mean displacement was 1.64±0.16 mm for the vEPO group and 1.56±0.15 mm for the vC-inoculated group. Cervical spinal cord with area of contusion on the right side is shown 1 day after impactor injury ( Figure 2a) . At 1 h after injury, 1 ml of vEPO or vC was injected in the injured spinal cord at two sites just above and below the epicenter of the impact (4 Â 10 7 PFU per ml). At 1 week post injury, the area of inflammatory infiltrate was determined by immunohistochemistry using an anti CD-45 (leukocyte common antigen) monoclonal antibody. Animals treated with vEPO had significantly reduced residual area of post-traumatic inflammatory response as compared with animals treated with vC ( Figure 2b ). Vascular extravasation of rat serum albumin (RSA) within the epicenter of the injured spinal cord was determined by immunohistochemistry and animals treated with vEPO had reduced area of RSA immunostaining compared with vC-treated animals (Figure 2c ), suggesting that vEPO reduced the post-traumatic alteration of vascular barrier. At 8 weeks post injury and vector delivery, the degree of tissue injury and tissue sparing resulting from vectormediated EPO expression was determined by analysis of hematoxylin and eosin-stained serial sections of cervical spinal cord at the epicenter of the lesion. Animals treated with vEPO had significantly reduced post-traumatic cavity area within the spinal cord as compared with animals treated with vC (vEPO ¼ 0.07 ± 0.03 mm 2 and vC ¼ 0.22 ± 0.04 mm 2 ; Po0.001), demonstrating decreased tissue damage (Figure 3a) . Measurements of spared gray and white matter tissue as percentage of total area of the cord showed that animals treated with vEPO had spared the gray matter preferentially when compared with vC-treated animals (vEPO ¼ 1.09 ± 0.31 mm 2 and vC ¼ 0.54 ± 0.12 mm 2 ; Po0.01; Figure 3b ). Although spared white matter area was also increased in vEPO-treated animals, the changes were mild and did not reach statistical significance.
Animals treated with vEPO show improved forelimb motor function after SCI Right forelimb function was assessed by modified forelimb motor rating scale, forepaw slips in the grid walk, paw reaching and preference in the cylinder test and the paw placement test. Animals injected intraspinally with vEPO 1 h after SCI showed a significantly higher right forelimb rating score, beginning at 2 week after injury and persisting over the course of 6 weeks post injury compared with the animals injected with control vector (Figure 4a) . A significant improvement in right forelimb stepping accuracy in the grid walk test was seen as early as 2 weeks in animals treated with vEPO compared with control ( Figure 4b ). Both vEPO-and vC-treated animals improved over 6 weeks of testing but vEPO-treated animals performed persistently better than vC-treated animals. Analysis of right forelimb reaching in cylinder test was also markedly improved and at 4 --6 weeks the forelimb performance was similar to sham animals ( Figure 4c) . However, the right paw placement elicited by vibrissa stimulation determined at 6 weeks after injury, although improved in vEPO-treated animals, did not reach statistical significance as the test produced significant variability within treatment cohorts ( Figure 4d ).
Intraspinal injection of vEPO improves hindlimb locomotor function after SCI. In addition to improvement in forelimb function, significant improvement in hindlimb locomotor function was observed in animals injected with vEPO compared with the animals injected with control vector. Beginning at 2 weeks after injury, animals injected with vEPO showed significantly higher Basso --Beattie --Bresnahan (BBB) score that persisted over the course of 6 weeks post injury compared with animals injected with control vector (Figure 5a ). A significant improvement in right hindlimb stepping accuracy in the grid walk test was seen beginning at 2 weeks and persisting up to 6 weeks ( Figure 5b ). Hindpaw print area and hindpaw width ratios determined by computerized digital gait instrument (Catwalk, Noldus, Attleboro, MA, USA) at 7 weeks after SCI were similarly improved in vEPOinjected compared with control vector-injected animals (Figures 5c and d).
Biochemical measures of recovery Neurofilaments (NFs), composed of NF-L, NF-M and NF-H subunits, are the most abundant structural components in large-diameter axons. 10 Unlike other intermediate filaments, NFs have characteristic 'side arms' extending from the filament backbone that are rich in serine and threonine residues. These lysine-serine-proline repeats in the carboxy-tails of NF-H and NF-M are recognized in their phosphorylated or dephosphorylated states by the antibodies SMI 31 and SMI 32, respectively.
The expression of cytoskeletal and synaptic proteins were evaluated in cervical spinal cords at the site of injury of animals killed either 2 weeks or 8 weeks post injury. The vEPO-treated animals had significantly higher levels of cytoskeletal proteins known to be most abundant in large-diameter axons, including nonphosphorylated and phosphorylated NF-H subunit and phosphorylated microtubule-associated protein tau, at 2 and 8 weeks post injury compared with vC ( Figure 6 ). Increased synaptic proteins PSD-95 (postsynaptic density protein 95), scaffolding protein anchoring glutamate receptors to the postsynaptic site and synaptophysin, associated with synaptic vesicles at the presynaptic site, were observed at 2 and 8 weeks, respectively, suggesting enhanced synaptic connectivity in vEPO-treated animals ( Figure 6 ). At 8 weeks following injury and vector delivery, EPO could still be detected in cervical cord of animals treated with vEPO but not in control animals (vEPO ¼ 1.72±0.42 ng mg --1 of protein vC ¼ below detection by ELISA), demonstrating continuous expression at low levels of the EPO transgene. We have used extensive behavioral testing of forelimb function to demonstrate that vector-mediated delivery of EPO shortly after cervical SCI results in substantial improvement in forelimb motor behavior. Upper extremity and hand weakness remains a critical problem for patients with cervical injuries as limitations in activities of daily living and ability to care for oneself become severely curtailed. We have also observed a mild improvement in hindlimb locomotor function. The improvement induced by vEPO occurred early after treatment, suggesting that minimizing the injury burden during the acute phase may underlie the early recovery of function that later translates in better preservation of spinal cord tissue or enhanced tissue sparing. In the spinal cord, EPO receptor (EPOR) is highly expressed in capillaries, especially in the white matter, in glial and neuronal elements including motor neurons of the ventral horn, and after injury synthesis of EPO lags temporally behind expression of EPOR. 11, 12 The diverse biological roles played by EPO in the nervous system following injury include preservation of vascular integrity, decrease in bleeding time and neovascularization, suppression of mononuclear cell infiltration and cytokine production, as well as prevention of apoptotic cell death. 13 NFs are the most prominent component of the axonal cytoskeleton and the number of NFs increases with axon caliber. Phosphorylated carboxy-tails of NF-H have been demonstrated to contribute to the expansion of large-diameter axons as they are most highly expressed in the internodal axolemma of large-diameter axons with much lower levels in small-diameter myelinated and unmyelinated fibers. 14 --16 The biochemical data support the conclusion that vEPO may contribute to the preservation of large-diameter axons, as indicated by phosphorylated cytoskeletal proteins at times that are presumed too early for substantial regeneration of large-caliber axons and may represent a reduction in early damage along the white matter tracts around the injury site.
The effect of vEPO on synaptic proteins may suggest enhanced synaptic connectivity within the gray matter near the lesion site as sprouting and short axon growth has been previously reported within similar time frame following SCI with different treatment modalities. In particular, EPO has been shown to enhance axon and dendrite growth in hippocampal neurons during early stages of development and promote outgrowth of dopaminergic neurons projecting to the striatum. 6, 17 Administration of recombinant EPO directly or released from hyaluronan --methylcellulose hydrogel has been used in animal models of acute thoracic SCI, 9, 18 leading to the initiation of clinical trials, 19 and intravenous administration of EPO prevents neuronal apoptosis in a model of subacute compression of the cervical spinal cord. 20 This study is the first to demonstrate the beneficial effects of vector-mediated delivery of EPO in acute cervical SCI. The importance of enhancing EPO expression at the injury site is the avoidance of complications resulting from systemic delivery including thrombocytosis, erythrocytosis, hypertension and others that may pose clinical risk and hamper recovery. Whereas recombinant EPO administered systemically has a half-life of hours and removal occurs via hepatic and renal clearance, vEPO has prolonged expression, with an initial peak of expression within the first 24 --72 h and decreasing but still detectable at 8 weeks post SCI and vector delivery. This time course may be important because proinflammatory cytokines induced EPOR expression while reducing expression of EPO, and the upregulation of EPOR expression may persists several weeks following SCI. 21, 22 The current results add to the body of literature supporting that early and sustained delivery of EPO following SCI may have important contributions toward clinical recovery.
The therapeutic window of opportunity for EPO following cervical SCI has not been established, nor its potential effects on long-distance axonal regeneration. These parameters are under consideration as we have recently published therapeutic applications of an HSV vector expressing EPO under a control of a regulatable expression cassette. 23 A similar HSV vector with a regulatable expression cassette under the control of the latencyassociated transcript HSV promoter for long-term expression of EPO is currently being tested in animal models of chronic disease and may be an appropriate therapeutic tool for cervical SCI.
MATERIALS AND METHODS

Vector construct
Full-length rat EPO was amplified from a cDNA library prepared from total RNA extracted from rat lung, cloned into BamH1 --EcoR1 cut HCMV-polyA/SASB3-16 and co-transfected with the nonreplicating HSV recombinant UL41E1G6 on 7b cells, a complementing cell line derived from African green monkey kidney (Vero) cells modified to provide the essential ICP4 and ICP27 gene products in trans. Clones were selected by identification of clear plaques, purified by limiting dilution and the EPO insert confirmed by PCR followed by DNA sequencing. The clone that expressed the highest levels of EPO on infection of 293 cells (designated vEPO) was propagated to high titer (4 Â 10 7 PFU per ml) and used in the experiments. Control vector vC is identical to vEPO except that a reporter gene for green fluorescent protein or LacZ was inserted in the expression cassette in place of the EPO gene (Figure 1) . The insertion sites of the transgenes in nonreplicating HSV constructs also differ from the nonreplicating HSV recombinants used in the previous studies. 6, 7 in that vector is defective in expression of four immediate early gene products and the transgene expression cassette has been placed into the ICP4 locus; similar to the HSV recombinant expressing preproenkephalin that is currently in clinical trial in patients with intractable pain from cancer. Figure 6 . Axonal cytoskeleton and synaptic proteins levels are increased in spinal cord after vEPO injection. Western blot analysis of non-phosphorylated neurofilament-H (non-P-NF-H) and NF-M measured using antibody SMI 32, phosphorylated NF-H and NF-M and phosphorylated tau protein measured by SMI 31 antibody were determined following injury and vector delivery. At both time points a marked increase in nonphosphorylated (a, b, i, j) and phosphorylated NF (c, d, k, l) and phosphorylated tau (e, f, m, n) was observed in animals treated with vEPO compared with vC. There were significant increases in PSD-95 at 2 weeks (g, h) and synaptophysin protein at 8 weeks (o, p) in the vEPO-treated animals as compared with vC-injected animals. Data presented as mean ± s.e.m. *Po0.05, **Po0.01, ***Po0.005; five animals per group.
Animal studies
Female Sprague --Dawley rats weighing 225 --250 g were housed one to three per cage B7 days before the beginning of the study with free access to food and water and maintained on a 12:12 light/dark schedule at 21 1C and 60% humidity. All housing conditions and experimental procedures were carried out in accordance with approved institutional animal care and use protocols. After acclimation, a 2-week period of training in all the behavioral tests was carried out. Then, under isoflurane anesthesia, a C5 --8 vertebral laminectomy was performed, exposing the C7 spinal cord segment without opening of the dura, and 160 Kdyne blunt force trauma was applied asymmetrically to the right dorsum of C7 spinal cord using a 1.5 mm diameter probe controlled by a computerized impactor device (Infinite Horizons, Precision Systems and Instrumentation, Lexington, KY, USA). At 1 h after injury, 1 ml volume containing 4 Â 10 10 PFU of either vEPO or vC was injected at two sites, 1 mm just above and 1 mm just below the site of impact on right side of the spinal cord at a depth of 1 mm and a rate of 0.5 ml min --1 (total injected volume 2 ml) through a 36-G beveled needle attached to a Nanofil syringe (World Precision Instruments, Sarasota, FL, USA) connected to a precision controlled pump (Harvard Instruments, Holliston, MA, USA). Sham animals underwent the same spinal cord exposure but no injury or injection was performed. For the behavioral analysis, there were eight animals in each SCI group (vEPO and vC) and four sham controls. At the conclusion of the behavioral experiments (8 weeks after injury), animals were perfused through the heart with 10 ml of phosphate-buffered saline (PBS) followed by 500 ml of 4% paraformaldehyde in PBS. The spinal cord was removed, postfixed at 4 1C overnight and cryoprotected with 30% sucrose in PBS. For protein analysis, at 2 and 8 weeks after injury, cohorts of animals were perfused through the heart with 100 ml of PBS and spinal cord removed and quickly frozen in dry ice.
Behavioral assessment
Open-field testing of forelimb function. Locomotion in the open field was tested as described. 25 The open-field environment consisted of a circular plexiglas enclosure 95 cm in diameter and 40 cm high with an antiskid floor. Rats were tested in pairs in a shadowy light to encourage locomotor activity. Animals that remained stationary for a period longer than 20 s were picked up and placed at the center of the open-field arena to reinitiate locomotion. All rats were scored over a time window of a maximum duration of 4 min, although the observation period was sometimes extended to make sure that the abilities of animals were not underestimated. Forelimb articular movements were evaluated during spontaneous locomotion. Joint movements at the wrist, elbow and shoulder were categorized as absent (score ¼ 0), slight (o50% of the maximum range of joint motion; score ¼ 1) or normal (450% of the maximum articular amplitude; score ¼ 2). Weight support was reported as being present (score ¼ 1) or absent (score ¼ 0) during stance ('stationary') and locomotion ('active'). The forelimb digit positions while the animal was stationary and during its displacements in the open field were scored as flexed (score ¼ 0) or atonic (score ¼ 1) corresponding to the position during 450% of the testing period. In locomotion, stepping was evaluated by rating the paw placement at the time of initial contact and during lift off; if placement was dorsal in 450% of the step cycles examined, a null score was attributed. In contrast, if the paw touched the ground with the plantar surface, the paw orientation relative to the body axis was scored. In a normal step cycle, the paw and body axes are parallel (score ¼ 2), whereas internal or external paw deviation (score ¼ 1) reflects impaired stepping. Paw orientation at lift was rated as parallel (score ¼ 2) or rotated internally or externally (score ¼ 1). During the swing phase, the limb movement was considered normal when the three main joints were moved in regular way (score ¼ 2); a jerky movement was categorized as irregular (score ¼ 1). Forelimb --hindlimb coordination was completed only if four consecutive steps occurred and if the affected limbs could support the body weight. The forelimb --hindlimb coordination was described as being absent (score ¼ 0), occasional (o50% of the time; score ¼ 1), frequent (50 --90% of the time; score ¼ 2) or consistent (490% of the time; score ¼ 3). An elevated tail position was rated as normal (score ¼ 1). The total possible score in normal animals is 20.
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Limb-use asymmetry test (cylinder test). Forelimb use during explorative activity was analyzed by putting rats in a transparent cylinder (20 cm diameter and 30 cm height) for 5 min or 20 touches during the trial. A mirror was placed behind the cylinder at an angle to enable the rater to record forelimb movements when the animal was turned away from the rater. The cylindrical shape encourages vertical exploration of the walls with the forelimbs as well as landing activity. A score for the right forelimb was calculated as the ratio of reaching movements with the right forepaw alone plus half the number of reaching movements with both paws together (simultaneously), divided by the total number of reaching movements (right paw, left paw plus both paws simultaneously).
Measurement of forelimb placing. Forelimb placing asymmetry was scored using the vibrissae-elicited forelimb placing test. 26 Animals were held by their torsos allowing forelimbs to hang free. While holding the animal, the experimenter made gentle up and down movements in space before place testing, which facilitated muscle relaxation and eliminated any struggling movements. Independent testing of each forelimb was induced by brushing the respective vibrissae on the edge of a table top once per trial for 10 trials. Intact animals place the forelimb of both sides quickly onto the countertop. Animals with unilateral damage, depending on the lesion site, will show varying degrees of impaired limb placing ability, while still placing the unimpaired limb reliably. A score of one was given each time the rat placed its forelimb on the edge of the tabletop in response to the vibrissae stimulation. Percent unsuccessful placing responses were determined (number incorrect Â 10) for impaired forelimb and nonimpaired responses. Typically, animals place successfully on 100% of the trials with the unimpaired limb; therefore, only the responses of the impaired limb are shown.
Grid walk. To assess placement of the paws we used a modification of the grid walk test that was initially developed to assess the ability of the animal to precisely control hindpaw placement. 27, 28 We placed the animals on a 50 cm runway with regularly spaced horizontal bars 1.0 cm apart. Performance on 20 cm of the runway was evaluated, with errors coded when the animal misplaced either the forepaw or the hindpaw, such that the paw fell through the space in the grid, up to a maximum of 20 missteps. Animals that did not display at least frequent stepping and were unable to cross the walkway were assigned the maximum score.
Open-field testing for hindlimb function: BBB test. Hindlimb performance was evaluated weekly for 5 weeks using the open-field locomotor test (BBB). 29 This testing was performed in the same environment used for the open-field forelimb test. Two examiners were positioned across from each other to observe both sides of the animal. Rats were tested either alone for 4 min or in pairs for 5 min. During open-field testing, rats were encouraged to locomote continuously. Rats that remained stationary for 415 --20 s were enticed to move by having them follow a pencil or a piece of paper, or by lightly tapping or scratching on the side of the open field. If the animal failed to respond to these stimuli, it was picked up by the forequarters and placed in the center of the open field, which usually caused it to move toward the side. The hindlimb movement rated on a 21-point scale, with a score of 0 corresponding to no observable hind limb movement and a score of 21 indicating normal locomotion. Plantar stepping with full weight support and complete forelimb --hindlimb coordination is reached when an animal shows a score of 14 points. 29 'CatWalk' automated gait analysis. The animals traverse a walkway (plexiglass walls, spaced 8 cm apart) with a glass floor (100 Â 15 Â 0.6 cm 3 ) (length Â width Â thickness) located in a darkened room. Light from an otherwise completely encased white fluorescent tube (length 110 cm, 30 W) enters the distal (from the observer) long edge of this glass floor. Sufficiently far from the edge, it strikes the surface below the critical angle and is entirely internally reflected. Only at those points where a paw touches the glass, light exits the floor and scatters at the paw, illuminating the points of contact only. Using a mirror, the corridor's floor was monitored by a Pulnix TM-765E CCD camera (Pulnix Inc., Basingstoke, UK) equipped with a wide angle objective (Cosimar 8.5 mm).
Primary cell culture
Primary spinal cord neurons from E17 rat pups were plated on 12-well plates coated with poly-D-lysine, at a concentration of 1.5 Â 10 6 cells per well and cultured in Neurobasal media containing B27, Glutamax I, Albumax II and penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). At 14 days in vitro, vectors vEPO or vC at a multiplicity of infection of 2 were added to the well for 2 h. At 2 and 3 days after infection, cell lysates of spinal cord neurons and their culture media were collected for western blot analysis and ELISA determination of transgene expression.
Western blot
Spinal cords around epicenter, 10 mm in length, were dissected and homogenized in lysis buffer containing 50 mM Tris, 10 mM NaCl, 1% Nonidet P-40, 0.02% NaN3, protease inhibitor and phosphatase inhibitor mixtures (Sigma, Saint Louis, MO, USA) at pH 7.4. Cultured E17 spinal cord neurons were collected in the same lysis buffer after being dislodged from the culture plates with a cell scraper. Cell lysates and tissue homogenates were sonicated and centrifuged at 10 000 g for 10 min at 4 1C. DRG cell cultures were centrifuged at 1000 g for 10 min at 4 1C. Protein concentration in tissue homogenates and cell lysates was determined using the BCA assay (Pierce/Thermo, Rockford, IL, USA) and spectrophotometry (AD340; Beckman Coulter, Brea, CA, USA). Aliquots containing 20 mg of protein were dissolved in Laemmli buffer and boiled at 95 1C for 5 min.
Proteins were separated on 4 --20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and then transferred onto a polyvinylidene diflouride membrane (Millipore, Billerica, MA, USA). Immunoblots were probed with primary antibody to anti-HA (1:1000, H6908, Sigma), antisynaptophysin 
Enzyme-linked immunosorbent assay
The amount of EPO released in vitro of produced in vivo was determined using a commercially available ELISA kit (R&D System, Minneapolis, MN, USA).
Reverse transcriptase-PCR
Total RNA was isolated from rat spinal cord via Trizol (Invitrogen). cDNA prepared from total RNA isolated from rat spinal cord was amplified using the following primer sets: b-actin forward (5 0 -CAGTTCGCCATGGATGACGAT ATC-3 0 ) and b-actin reverse (5 0 -CACGCTCGGTCAGGATCTTCATG-3 0 ) for b-actin and EPO forward (5 0 -CCGGAATTCGCCAGGCGCGGAGATG-3 0 ) and HA reverse (5 0 -CGGGATCCTCAAGCGTAATCTGGAACATC-3 0 ) for EPO. Amplification was carried out by denaturation at 94 1C for 5 min followed by 28 cycles (94 1C for 30 s, 68 1C for 3 min, and 1 cycle at 68 1C for 8 min) using a GeneAmp PCR 2700 (Applied Biosystems, Foster City, CA, USA).
Measurement of the lesion properties
At 8 weeks post injury and vector injection, cervical spinal cord was removed, postfixed, cryoprotected and blocked in 3 mm segments. Using a cryostat (Leica, Buffalo Grove, IL, USA), 20 mm serial sections of spinal cord were obtained from the 3 mm segment containing the epicenter of the lesion and every third section was mounted onto cold Superfrost glass slides (Fisher Scientific, Pittsburgh, PA, USA), heated at 37 1C and stained with hematoxylin --eosin following standard protocol. At the epicenter of the lesion, three sections per animal were analyzed and the area of preserved gray and white matter determined from images captured using a Nikon Eclipse E1000 microscope (Nikon Instruments, Melville, NY, USA) equipped with a Plan Apo2X/0.1 lens using Metamorph 7.0 software (Molecular Devices, Palo Alto, CA, USA). Sections from eight animals were examined in each group.
Immunohistochemistry for inflammation and RSA extravasation At 1 week post injury and vector injection, cervical spinal cord was removed, post-fixed, cryoprotected and blocked in 3 mm segments. Serial sections of spinal cord obtained from the 3 mm segment containing the epicenter of the lesion as previously described were examined for CD-45 using an anti-CD-45 monoclonal antibody (1:1000, mcd4500, Invitrogen) followed by complementary secondary tagged fluorescent antibody (1:1000, a11029, Invitrogen) or examined for RSA extravasation using an anti-RSA goat polyclonal antibody (1:500, 0213-0341, Cappel, Cochranville, PA, USA) followed by DyLight 488 AffiniPure bovine anti-goat IgG (1:500, 805-485-180, Jackson ImmunoResearch, West Grove, PA, USA). Measurements of the immunostained areas were obtained from images captured as described above using Metamorph 7.0 software. Three sections from six animals were examined in each group.
Statistical analysis
The statistical significance of the difference between groups for the western blot results was determined by one-way analysis of variance (SPSS 12.0, Armonk, NY, USA) using Bonferonni's correction for the multiple post hoc analyses. Repeated behavioral measures were analyzed using the repeated measures general linear model with post hoc tests for the time points that were significant between treatments corrected for multiple comparisons using both Tukey and Bonferroni corrections. All results are expressed as mean ± s.e.m. with Po0.05 considered significant.
